| Title: | Association of estimated glucose disposal rate with atrial fibrillation, heart failure and cardiovascular mortality in patients with diabetes: a prospective cohort study from the UK Biobank |
| Journal: | Frontiers in Endocrinology |
| Published: | 18 Jul 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40756509/ |
| DOI: | https://doi.org/10.3389/fendo.2025.1579836 |
| URL: | http://dx.doi.org/10.3389/fendo.2025.1579836 |
Publication 16145
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Estimated glucose disposal rate (eGDR) was a novel non-insulin-based marker of insulin resistance (IR), which had been used in many studies to evaluate the clinical prognosis of diabetes. However, the association of eGDR with atrial fibrillation (AF), heart failure (HF) and cardiovascular mortality in patients with diabetes remains unclear.</p>
Methods: The study utilized UK Biobank data from 31,733 participants. Kaplan-Meier curves and Log-rank tests assessed AF, HF, and cardiovascular mortality incidence. Multivariate Cox models and restricted cubic splines analyzed the associations of eGDR with these outcomes. Polygenic Risk Score (PRS) analysis evaluated the joint effects of eGDR and PRS. Boruta algorithm filtered key predictive variables. Subgroup analysis was performed using cardiovascular high-risk factors, and mediation analysis explored the relationships of eGDR with the outcomes.</p>
Results: Subjects with higher eGDR were more likely to be female, younger, more physically active, non-smoker, and non-drinker. The cumulative incidence of AF, HF, and cardiovascular mortality in the higher quartiles of GDR were significantly lower than those in the lowest quartile (log-rank P < 0.001 for all). eGDR exhibited an independent negative linear correlation with the risk of AF (HR = 0.94, 95% CI: 0.91-0.96), HF (HR = 0.78, 95% CI: 0.74-0.82), and cardiovascular mortality (HR = 0.86, 95% CI: 0.83-0.88) risk. eGDR made the most significant contribution to the predicted outcomes. In diabetic patients with high genetic susceptibility, high eGDR could reduce the risk of AF (HR = 0.68, 95% CI: 0.51-0.90), HF (HR = 0.43, 95% CI: 0.29-0.62), and cardiovascular mortality (HR = 0.30, 95% CI: 0.22-0.42). Mediation analysis demonstrated that 10.7%, 7.9%, and 10.3% of the relationship between eGDR and AF, HF, and cardiovascular mortality among individuals with diabetes were mediated by eGFR, respectively.</p>
Conclusions: This study demonstrated that higher eGDR levels were associated with a decreased risk of AF, HF, and cardiovascular mortality. Therefore, eGDR may serve as a valuable tool for predicting the risk of AF, HF, and cardiovascular mortality in patients with diabetes.</p>
18 Keywords
- Aged
- Atrial Fibrillation
- Biological Specimen Banks
- Blood Glucose
- Cardiovascular Diseases
- Diabetes Mellitus
- Female
- Heart Failure
- Humans
- Incidence
- Insulin Resistance
- Male
- Middle Aged
- Prognosis
- Prospective Studies
- Risk Factors
- UK Biobank
- United Kingdom
7 Authors
- Zhen Tan
- Yijun Liu
- Lei Liu
- Shuang Li
- Xinrui Xue
- Xiaoping Li
- Hongqiang Ren
1 Application
| Application ID | Title |
|---|---|
| 69407 | Characterization of actionable pharmacogenetic (PGx) variation across population-based cohorts |
Enabling scientific discoveries that improve human health